Voxelotor (Oxbryta®) – Haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years.

Characteristics

Start date 15.05.2022
Resolution 03.11.2022
INN Voxelotor
Brand name Oxbryta®
Pharm. company Global Blood Therapeutics Germany GmbH
G-BA procedure ID 2022-05-15-D-813
ATC code B06AX03
ICD-10 codes D57.0Sickle-cell disease NOS with crisis, D57.1Hb-SS disease without crisis
Therapeutic area Hematopoietic diseases ORPHAN
Reason for procedure Initial assessment

G-BA resolution "Anwendungsgebiet des Beschlusses" (German)

Oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (SCD) in

adults and paediatric patients 12 years of age and older as monotherapy or in combination with

hydroxycarbamide

Subpopulation Indication Comparator
Oxbryta is used in adults, children and adolescents aged 12 and over for the treatment of haemolytic anaemia due to sickle cell disease as a monotherapy or in combination with hydroxycarbamide. – (Orphan drug)

9. Associated procedures



<< List of all resolutions

Log in to read more ...

The AMNOG monitor is a subscription-based service for pharmaceutical manufacturers and institutions. Enter your account details here in order to analyse the results of the early benefit assessment in Germany – or contact us for more information.